ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
The company informs the exchange that it has sent letters to shareholders with unregistered email addresses, providing a weblink for the AGM Notice and Integrated Annual Report.
Hemant Surgical Industries Ltd has filed its Integrated Annual Report and Notice of the 37th Annual General Meeting for the financial year 2025-26.
Hemant Surgical Industries Ltd has scheduled its 37th Annual General Meeting for September 29, 2026, to be conducted through video conferencing.
Hemant Surgical Industries approved its Directors' Report and Management Discussion and Analysis for FY2026, and scheduled its 37th Annual General Meeting for September 29, 2026.
Hemant Surgical Industries signed a manufacturing agreement with Sonomed Escalon, USA for ophthalmic ultrasound devices. The deal establishes local SKD manufacturing and exclusive distribution rights within India.
Hemant Surgical acquired a 66.66% stake in Lifesenz Cancer Research Labs for ₹19.98 Crore. The deal expands the company's footprint into the precision oncology segment.
Hemant Surgical Industries completed the acquisition of Lifesenz Cancer Research Labs Private Limited. The target entity officially became a subsidiary effective June 01, 2026.
Hemant Surgical Industries Ltd declared non-applicability of the Annual Secretarial Compliance Report for FY 2025-26. The company cited exemptions available to listed SME entities.
Hemant Surgical Industries will acquire a 66.66% stake in Lifesenz Cancer Research Labs for ₹19.99 Crore. The acquisition strengthens its healthcare and cancer diagnostic segments.
Singularity Large Value Fund III converted warrants into 6,49,600 equity shares of Hemant Surgical Industries. The fund's stake increased to 6.19% following this conversion.
Hemant Surgical Industries Ltd reported revenue from operations of ₹167.2 Cr (+189.3% YoY) and net profit of ₹12.7 Cr (+159.2% YoY) for H2 FY26.
Hemant Surgical Industries scheduled a board meeting on May 15, 2026. Directors will approve audited standalone and consolidated financial results for the 2026 fiscal year.
Hemant Surgical Industries Ltd submitted its quarterly compliance certificate under SEBI (DP) Regulations for the period ended March 31, 2026. The company confirmed that all shares remain in dematerialized form and no rematerialisation requests were received. This is a routine regulatory update with no material financial impact.